Strong Response to SARS-CoV-2 Vaccine Additional Doses Among Patients With Inflammatory Bowel Diseases

PREVENT-COVID Study Group

doi:10.1016/j.cgh.2022.01.056

Strong Response to SARS-CoV-2 Vaccine Additional Doses Among Patients With Inflammatory Bowel Diseases

PREVENT-COVID Study Group

Research output: Contribution to journal › Short survey › peer-review

Original language	English (US)
Pages (from-to)	1881-1883.e1
Journal	Clinical Gastroenterology and Hepatology
Volume	20
Issue number	8
DOIs	https://doi.org/10.1016/j.cgh.2022.01.056
State	Published - Aug 2022

ASJC Scopus subject areas

Gastroenterology
Hepatology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.cgh.2022.01.056

Cite this

@article{1cc91e543562412db641b86b28e2f86f,

title = "Strong Response to SARS-CoV-2 Vaccine Additional Doses Among Patients With Inflammatory Bowel Diseases",

author = "{PREVENT-COVID Study Group} and Long, {Millie D.} and Weaver, {Kimberly N.} and Xian Zhang and Kelly Chun and Kappelman, {Michael D.} and R. Watkins and J. Adler and Dubinsky, {M. C.} and A. Kastl and A. Bousvaros and Strople, {J. A.} and Cross, {R. K.} and Higgins, {P. D.R.} and Ungaro, {R. C.} and M. Bewtra and E. Bellaguarda and Farraye, {F. A.} and Boccieri, {M. E.} and A. Firestine and M. Fernando and M. Bastidas and M. Zikry and X. Dai",

note = "Funding Information: Funding This research was funded by the Helmsley Charitable Trust, United States . Funding Information: Funding This research was funded by the Helmsley Charitable Trust, United States. Conflicts of interest These authors disclose the following: Millie D. Long has received research/grants from Pfizer, Inc, and has consulted for AbbVie, Inc, Bristol-Myers Squibb Company, Calibr, Eli Lilly and Company, Genentech, Inc, Gilead Sciences, Inc, Janssen Pharmaceuticals, Inc, Pfizer Inc, Roche, Takeda Pharmaceuticals U.S.A., Inc, TARGET PharmaSolutions, Inc, and Theravance Biopharma; Kimberly N. Weaver has consulted for AbbVie; Kelly Y. Chun is an employee of LabCorp; and Michael D. Kappelman has consulted for AbbVie, Janssen, Pfizer, and Takeda, is a shareholder in Johnson & Johnson, and has received research support from Pfizer, Takeda, Janssen, AbbVie, Lilly, Genentech, Boehringer Ingelheim, Bristol Myers Squibb, Celtrion, and Arenapharm. The remaining authors disclose no conflicts. PREVENT-COVID Study Group The PREVENT-COVID Study Group members include the following: R. Watkins (Division of Pediatric Gastroenterology and Nutrition, University of Maryland School of Medicine, Baltimore, Maryland), J. Adler (Susan B. Meister Child Health Evaluation and Research Center, Department of Pediatrics, University of Michigan, Ann Arbor, Michigan), M.C. Dubinsky (Department of Pediatrics, Susan and Leonard Feinstein IBD Center, Icahn School of Medicine at Mount Sinai, New York, New York), A. Kastl (Division of Gastroenterology, Children's Hospital of Philadelphia, Perelman School of Medicine, Philadelphia, Pennsylvania), A. Bousvaros (Children's Hospital Boston, Boston, Massachusetts), J.A. Strople (Ann and Robert H. Lurie Children's Hospital of Chicago), R.K. Cross (Division of Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, Maryland), P.D.R. Higgins (Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan), R.C. Ungaro (Susan and Leonard Feinstein IBD Center, Icahn School of Medicine at Mount Sinai, New York, New York), M. Bewtra (Division of Gastroenterology, Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania), E. Bellaguarda (Division of Gastroenterology and Hepatology, Northwestern University, Chicago, Illinois), F.A. Farraye (Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida), M.E. Boccieri and A. Firestine (Division of Pediatric Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina), M. Fernando, M. Bastidas, and M. Zikry (Esoterix Specialty Laboratory, LabCorp, Calabasas, California), and X. Dai (Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina) Conflicts of interest The PREVENT-COVID Study Group members disclose the following: Jeremy Adler has consulted for Janssen, and has received research support from The Gary and Rachel Glick Charitable Fund, Shaevsky Family Research Fund for Crohn's Disease, the Crohn's & Colitis Foundation, and The Leona M. and Harry B. Helmsley Charitable Trust; M.C. Dubinsky has received consultant fees from AbbVie, Arena, Bristol Myers Squibb, Celgene, Eli Lilly, Gilead, Janssen, Pfizer, Prometheus Labs, and Takeda, has received grant support from AbbVie and Prometheus Labs, and has received license fees from Takeda; Athos Bousvaros has received research support (subinvestigator on protocols) from the following companies: Janssen, AbbVie, Takeda, Buhlmann, Arena, and Eli Lilly, has consulted for Arena, Best Doctors, Eli Lilly, and Takeda, and has received royalties from Up to Date; Raymond K. Cross has participated in advisory boards and consulted for AbbVie, Bristol Myers Squibb, Eli Lilly, Janssen, LabCorp, Pfizer, Samsung Bioepis, and Takeda; P.D.R. Higgins has consulted for AbbVie, Pfizer, and Takeda, and has received grant support from the National Institutes of Health, CCF, AbbVie, Pfizer, Takeda, Genentech, Eli Lilly, Arena, and the Rainin Foundation; Ryan C. Ungaro has served as an advisory board member or consultant for AbbVie, Bristol Myers Squibb, Eli Lilly, Janssen, Pfizer, and Takeda, has received research support from AbbVie, Boehringer Ingelheim, and Pfizer; Meena Bewtra has received research funding from Janssen, GlaxoSmithKline, and Takeda, has served as a consultant for Janssen, AbbVie, BMS, and Pfizer, and has received honorarium for participation in a continuing medical education program sponsored by AbbVie; Emanuelle Bellaguarda has consulted for AbbVie, Pfizer, and Bristol Myers Squibb; F.A. Farraye is a consultant for Arena, BMS, Braintree Labs, Gilead, GI Reviewers, Innovation Pharmaceuticals, Iterative Scopes, Janssen, Pfizer, and Sebela, and is a member of the Data Safety Monitoring Board for Lilly and Theravance; and Manory Fernando, Monique Bastidas, and Michael Zikry are employees of LabCorp. The remaining PREVENT-COVID Study Group members disclose no conflicts.",

year = "2022",

month = aug,

doi = "10.1016/j.cgh.2022.01.056",

language = "English (US)",

volume = "20",

pages = "1881--1883.e1",

journal = "Clinical Gastroenterology and Hepatology",

issn = "1542-3565",

publisher = "W.B. Saunders Ltd",

number = "8",

}

TY - JOUR

T1 - Strong Response to SARS-CoV-2 Vaccine Additional Doses Among Patients With Inflammatory Bowel Diseases

AU - PREVENT-COVID Study Group

AU - Long, Millie D.

AU - Weaver, Kimberly N.

AU - Zhang, Xian

AU - Chun, Kelly

AU - Kappelman, Michael D.

AU - Watkins, R.

AU - Adler, J.

AU - Dubinsky, M. C.

AU - Kastl, A.

AU - Bousvaros, A.

AU - Strople, J. A.

AU - Cross, R. K.

AU - Higgins, P. D.R.

AU - Ungaro, R. C.

AU - Bewtra, M.

AU - Bellaguarda, E.

AU - Farraye, F. A.

AU - Boccieri, M. E.

AU - Firestine, A.

AU - Fernando, M.

AU - Bastidas, M.

AU - Zikry, M.

AU - Dai, X.

N1 - Funding Information: Funding This research was funded by the Helmsley Charitable Trust, United States . Funding Information: Funding This research was funded by the Helmsley Charitable Trust, United States. Conflicts of interest These authors disclose the following: Millie D. Long has received research/grants from Pfizer, Inc, and has consulted for AbbVie, Inc, Bristol-Myers Squibb Company, Calibr, Eli Lilly and Company, Genentech, Inc, Gilead Sciences, Inc, Janssen Pharmaceuticals, Inc, Pfizer Inc, Roche, Takeda Pharmaceuticals U.S.A., Inc, TARGET PharmaSolutions, Inc, and Theravance Biopharma; Kimberly N. Weaver has consulted for AbbVie; Kelly Y. Chun is an employee of LabCorp; and Michael D. Kappelman has consulted for AbbVie, Janssen, Pfizer, and Takeda, is a shareholder in Johnson & Johnson, and has received research support from Pfizer, Takeda, Janssen, AbbVie, Lilly, Genentech, Boehringer Ingelheim, Bristol Myers Squibb, Celtrion, and Arenapharm. The remaining authors disclose no conflicts. PREVENT-COVID Study Group The PREVENT-COVID Study Group members include the following: R. Watkins (Division of Pediatric Gastroenterology and Nutrition, University of Maryland School of Medicine, Baltimore, Maryland), J. Adler (Susan B. Meister Child Health Evaluation and Research Center, Department of Pediatrics, University of Michigan, Ann Arbor, Michigan), M.C. Dubinsky (Department of Pediatrics, Susan and Leonard Feinstein IBD Center, Icahn School of Medicine at Mount Sinai, New York, New York), A. Kastl (Division of Gastroenterology, Children's Hospital of Philadelphia, Perelman School of Medicine, Philadelphia, Pennsylvania), A. Bousvaros (Children's Hospital Boston, Boston, Massachusetts), J.A. Strople (Ann and Robert H. Lurie Children's Hospital of Chicago), R.K. Cross (Division of Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, Maryland), P.D.R. Higgins (Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan), R.C. Ungaro (Susan and Leonard Feinstein IBD Center, Icahn School of Medicine at Mount Sinai, New York, New York), M. Bewtra (Division of Gastroenterology, Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania), E. Bellaguarda (Division of Gastroenterology and Hepatology, Northwestern University, Chicago, Illinois), F.A. Farraye (Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida), M.E. Boccieri and A. Firestine (Division of Pediatric Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina), M. Fernando, M. Bastidas, and M. Zikry (Esoterix Specialty Laboratory, LabCorp, Calabasas, California), and X. Dai (Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina) Conflicts of interest The PREVENT-COVID Study Group members disclose the following: Jeremy Adler has consulted for Janssen, and has received research support from The Gary and Rachel Glick Charitable Fund, Shaevsky Family Research Fund for Crohn's Disease, the Crohn's & Colitis Foundation, and The Leona M. and Harry B. Helmsley Charitable Trust; M.C. Dubinsky has received consultant fees from AbbVie, Arena, Bristol Myers Squibb, Celgene, Eli Lilly, Gilead, Janssen, Pfizer, Prometheus Labs, and Takeda, has received grant support from AbbVie and Prometheus Labs, and has received license fees from Takeda; Athos Bousvaros has received research support (subinvestigator on protocols) from the following companies: Janssen, AbbVie, Takeda, Buhlmann, Arena, and Eli Lilly, has consulted for Arena, Best Doctors, Eli Lilly, and Takeda, and has received royalties from Up to Date; Raymond K. Cross has participated in advisory boards and consulted for AbbVie, Bristol Myers Squibb, Eli Lilly, Janssen, LabCorp, Pfizer, Samsung Bioepis, and Takeda; P.D.R. Higgins has consulted for AbbVie, Pfizer, and Takeda, and has received grant support from the National Institutes of Health, CCF, AbbVie, Pfizer, Takeda, Genentech, Eli Lilly, Arena, and the Rainin Foundation; Ryan C. Ungaro has served as an advisory board member or consultant for AbbVie, Bristol Myers Squibb, Eli Lilly, Janssen, Pfizer, and Takeda, has received research support from AbbVie, Boehringer Ingelheim, and Pfizer; Meena Bewtra has received research funding from Janssen, GlaxoSmithKline, and Takeda, has served as a consultant for Janssen, AbbVie, BMS, and Pfizer, and has received honorarium for participation in a continuing medical education program sponsored by AbbVie; Emanuelle Bellaguarda has consulted for AbbVie, Pfizer, and Bristol Myers Squibb; F.A. Farraye is a consultant for Arena, BMS, Braintree Labs, Gilead, GI Reviewers, Innovation Pharmaceuticals, Iterative Scopes, Janssen, Pfizer, and Sebela, and is a member of the Data Safety Monitoring Board for Lilly and Theravance; and Manory Fernando, Monique Bastidas, and Michael Zikry are employees of LabCorp. The remaining PREVENT-COVID Study Group members disclose no conflicts.

PY - 2022/8

Y1 - 2022/8

UR - http://www.scopus.com/inward/record.url?scp=85129602591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85129602591&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2022.01.056

DO - 10.1016/j.cgh.2022.01.056

M3 - Short survey

C2 - 35150924

AN - SCOPUS:85129602591

SN - 1542-3565

VL - 20

SP - 1881-1883.e1

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

IS - 8

ER -

Strong Response to SARS-CoV-2 Vaccine Additional Doses Among Patients With Inflammatory Bowel Diseases

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this